Medtronic has agreed to sell its patient care, deep vein thrombosis, and nutritional insufficiency business lines – deemed to be lower-growth, lower-margin assets – to Cardinal Health in an all-cash deal worth $6.1bn.
The significant liquidity which Medtronic will benefit from this deal will immediately boost Medtronic's top line and help bulk up its operating margins. The bottom line will be diluted modestly,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?